283 related articles for article (PubMed ID: 36281789)
21. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
Chen Y
Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
[TBL] [Abstract][Full Text] [Related]
22. The m6A reader IGF2BP2 promotes the progression of esophageal squamous cell carcinoma cells by increasing the stability of OCT4 mRNA.
Zhao R; Li T; Zhao X; Yang Z; Ma L; Wang X
Biochem Cell Biol; 2024 Apr; 102(2):169-178. PubMed ID: 37917979
[TBL] [Abstract][Full Text] [Related]
23. KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma.
Cai H; Liang J; Jiang Y; Wang Z; Li H; Wang W; Wang C; Hou J
J Exp Clin Cancer Res; 2024 Mar; 43(1):69. PubMed ID: 38443991
[TBL] [Abstract][Full Text] [Related]
24. Identification of genetic mechanisms underlying lipid metabolism-mediated tumor immunity in head and neck squamous cell carcinoma.
Liu S; Wang S; Wang Z
BMC Med Genomics; 2023 May; 16(1):110. PubMed ID: 37210507
[TBL] [Abstract][Full Text] [Related]
25. The m
Romanowska K; Rawłuszko-Wieczorek AA; Marczak Ł; Kosińska A; Suchorska WM; Golusiński W
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34207099
[TBL] [Abstract][Full Text] [Related]
26. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
[TBL] [Abstract][Full Text] [Related]
27. Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma.
Zhao L; Liang J; Zhong W; Han C; Liu D; Chen X
Gene; 2022 Jun; 827():146461. PubMed ID: 35358652
[TBL] [Abstract][Full Text] [Related]
28. Homeobox-D 1 and FTO form a transcriptional-epigenetic feedback loop to promote head and neck cancer proliferation.
Zhang C; Xie L; Lin Z
Cell Biol Int; 2023 Dec; 47(12):1987-1998. PubMed ID: 37655555
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.
Ahirwar SS; Lasunte S; Gupta M; Chowdhary R; Kotnis A
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3525-3535. PubMed ID: 37898859
[TBL] [Abstract][Full Text] [Related]
30. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma.
Zhang T; Sheng P; Jiang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2805-2822. PubMed ID: 35780396
[TBL] [Abstract][Full Text] [Related]
31. Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
Gao ZW; Yang L; Liu C; Wang X; Guo WT; Zhang HZ; Dong K
Front Immunol; 2022; 13():903461. PubMed ID: 35663977
[TBL] [Abstract][Full Text] [Related]
32. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
[TBL] [Abstract][Full Text] [Related]
33. Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma.
Yue Q; Xu L; Zhang D
Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):704-709. PubMed ID: 36416324
[TBL] [Abstract][Full Text] [Related]
34. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
[TBL] [Abstract][Full Text] [Related]
35. Molecular Characteristics, Prognostic Value, and Immune Characteristics of m
Geng X; Zhang Y; Zeng Z; Zhu Z; Wang H; Yu W; Li Q
Front Oncol; 2021; 11():629718. PubMed ID: 33816266
[TBL] [Abstract][Full Text] [Related]
36. Integrated analysis of the prognostic values of RNA-binding proteins in head and neck squamous cell carcinoma.
Wu ZH; Yue JX; Zhou T; Xiao HJ
Biofactors; 2021 May; 47(3):478-488. PubMed ID: 33651487
[TBL] [Abstract][Full Text] [Related]
37. NUTF2 as a Prognostic Indicator and Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Li P; Wen X; Zhang X; Wang F; Zhang D; Shang H
Genet Test Mol Biomarkers; 2022 Dec; 26(12):553-563. PubMed ID: 36577127
[No Abstract] [Full Text] [Related]
38. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma.
Zhou C; Wang S; Shen Z; Shen Y; Li Q; Shen Y; Huang J; Deng H; Ye D; Zhan G; Li J
J Clin Lab Anal; 2022 Jan; 36(1):e24113. PubMed ID: 34783061
[TBL] [Abstract][Full Text] [Related]
39. Exostoisns (EXT1/2) in Head and Neck Cancers: An In Silico Analysis and Clinical Correlates.
Wang Y; Huang Y; Zhu H; Guo Z; Cheng J; Zhang C; Zhong M
Int Dent J; 2024 Jun; 74(3):446-453. PubMed ID: 37989698
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
